Literature DB >> 12213417

Cimetidine prevents suppression of delayed hypersensitivity in an animal model of haemorrhagic shock.

Peter MacD Hewitt1, Neil Armstrong, Patricia Bowrey, Maya Cherian, David Lawson Morris.   

Abstract

BACKGROUND: Cimetidine reverses immunosuppression following trauma, however, its effect on pure haemorrhagic shock is unknown.
METHODS: Mice sensitized by injection of sheep red blood cells (SRBCs), were subjected to cardiac puncture and randomized to a control group-A (n=11) and three shock groups (35% of blood volume extracted): group-S had no treatment (n=16), group-CP received cimetidine 50mg/kg intraperitoneally (n=16), group-CW received oral cimetidine (200mg/kg per day, n=16). After 5 days, animals were challenged by injection of SRBCs into the foot-pad of the right hind paw (same volume of saline was injected into left paw). Foot-pad thickness ratios (FPTRs) were determined at 16 and 40 h, and inflammatory response was assessed histologically.
RESULTS: At 16 h, FPTRs were greater in group-CW than group-S (P=0.01). There were no differences at 40 h. More animals in groups-CP and -CW had grade 3/4 inflammation, whilst group-S had the least inflammatory response (NS).
CONCLUSIONS: Cimetidine prevents suppression of delayed hypersensitivity in this model.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12213417     DOI: 10.1016/s0020-1383(02)00095-5

Source DB:  PubMed          Journal:  Injury        ISSN: 0020-1383            Impact factor:   2.586


  2 in total

1.  Anti-FcεR1 antibody injections activate basophils and mast cells and delay Type 1 diabetes onset in NOD mice.

Authors:  Marc P Hübner; David Larson; Marina N Torrero; Ellen Mueller; Yinghui Shi; Kristin E Killoran; Edward Mitre
Journal:  Clin Immunol       Date:  2011-08-23       Impact factor: 3.969

Review 2.  Experimental trauma models: an update.

Authors:  Michael Frink; Hagen Andruszkow; Christian Zeckey; Christian Krettek; Frank Hildebrand
Journal:  J Biomed Biotechnol       Date:  2011-01-26
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.